ArticleBMC psychiatry2025
The OXT rs6133010 variant modulates susceptibility to psychiatric symptoms during withdrawal in patients with alcohol dependence.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations of resistance liuzijue qigong with sleep and mood in chronic insomnia: a pilot open-label Non-randomized trial.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlcohol dependence (AD) confers susceptibility to distressing withdrawal symptoms that often lead to relapse. While neuroadaptation during withdrawal influences symptoms, the genetic factors behind it have not been thoroughly investigated. We utilized propensity score matching and investigated connections between AD, OXT rs6133010, and withdrawal symptoms to address confounding variables. By elucidating the OXT rs6133010-AD interaction, we aim to gain insights into alcohol withdrawal variability and contribute to personalized treatment approaches.
methodsA cross-sectional study design was employed involving a total of 389 AD patients and 184 healthy controls who were genotyped for the OXT rs6133010 polymorphism. Psychiatric symptoms were evaluated using standardized scales during early withdrawal. Propensity score matching mitigated age and education differences.
resultsA two-way ANOVA demonstrated a significant AD x OXT rs6133010 interaction effect on hostility and anxiety. Further analysis revealed that the regulatory impact of OXT rs6133010 was exclusively in AD patients. Specifically, AD patients with the AA homozygote showed robust protection against hostility and anxiety. Path analysis unveiled the underlying mechanism of OXT symptom regulation.
conclusionThis study presents novel evidence that OXT rs6133010 specifically modulates psychiatric symptoms in AD. The G allele may heighten hostility and anxiety vulnerability during alcohol withdrawal. These findings emphasize considering environmental factors when studying and utilizing oxytocin therapeutically. Additionally, OXT may not directly act as an anxiolytic but instead regulates anxiety by modulating hostility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.